Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUGUSTUS
2014-002004-24Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of apixaban, warfarin and aspirin in Atrial fibrillation (AFib), acute coronary syndrome (ACS) and coronary arteriosclerosis (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: ISTH major or clinically relevant non-major bleeding. Started Aug 2016; status: completed.
02
Drugs
apixabanwarfarinaspirin
03
Conditions
Atrial fibrillation (AFib)acute coronary syndrome (ACS)coronary arteriosclerosis
Beyond the preview
Go deeper on 2014-002004-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002004-24.